कंपनी का अवलोकन
Biofrontera Inc. (BFRI) operates as a biopharmaceutical entity focused on the commercialization of pharmaceutical products designed to treat various dermatological conditions within the United States. The company specializes in the development and marketing of specific therapeutic solutions, including Ameluz, BF-RhodoLED, and the RhodoLED lamp series, which are utilized for the treatment of actinic keratosis. This business falls under the Healthcare sector and specifically within the Drug Manufacturers - Specialty & Generic industry, indicating a focus on niche therapeutic areas rather than mass-market commodities. With a market capitalization of $12.11M, an annual revenue of $41.70M, and a workforce of 84 employees, the company represents a small-cap entity with a limited operational footprint. These financial metrics suggest that Biofrontera functions as a micro-cap company, where revenue generation is relatively modest compared to large-cap peers, and the small employee base implies a lean organizational structure typical of early-stage or specialized pharmaceutical firms.
वित्तीय स्वास्थ्य
The company reported a revenue of $41.70M over the trailing twelve months, yet this figure masks a significant operational challenge as it was accompanied by a net income of $-10,536,000 and an EBITDA of $-11,210,000. The substantial disparity between positive revenue and negative net income reveals a cost structure where operating expenses and costs of goods sold far exceed the gross revenue generated, a common characteristic in drug development and commercialization phases. Free cash flow stands at $-2,362,000, indicating that the company is burning cash to fund its operations and growth initiatives, which limits immediate financial flexibility for large-scale acquisitions or heavy dividend payments. Profitability metrics further highlight this struggle, with a gross margin of 73.7% suggesting efficient production or pricing power, contrasted by an operating margin of 26.7% and a negative profit margin of -25.3%, signaling that high overhead costs are eroding bottom-line earnings. Regarding liquidity, the firm holds $6.40M in cash against $6.16M in debt, resulting in a debt-to-equity ratio of 58.79, which presents a leveraged balance sheet where liabilities approach the level of liquid assets. However, the current ratio of 1.52 suggests that the company maintains adequate short-term liquidity to cover its immediate obligations without immediate distress. Return on equity is reported at -141.3% and return on assets at -28.0%, metrics that reveal management has yet to generate positive returns on the capital invested by shareholders or utilized in operations, reflecting the current stage of business development.
मूल्यांकन आकलन
Valuation multiples for Biofrontera present a complex picture, with a P/E ratio (TTM) listed as N/A due to losses, while the forward P/E stands at -4.52, implying that the market expects earnings to remain negative or that traditional earnings-based valuation methods are currently inapplicable. The price-to-book ratio is 1.16, indicating that the market values the company slightly above its tangible book value, which may reflect intangible assets like intellectual property or future growth potential despite current losses. Alternative valuation metrics provide additional context, with a price-to-sales ratio of 0.29 and an EV/EBITDA of -1.06, suggesting that the stock is priced at a fraction of its sales revenue, a common feature for pre-profitability biotech firms. In terms of trading range, the stock has a 52-week high of $1.19 and a 52-week low of $0.54, meaning the current price sits dynamically within this band, fluctuating based on sector sentiment and specific product pipeline news. The beta value of 0.64 indicates that the stock is less volatile than the broader market, moving with roughly 36% less intensity than the overall index, which suggests a lower risk profile regarding price swings for long-term holders.
Growth & Income
Growth dynamics for Biofrontera are characterized by a robust revenue growth rate of 36.2% year-over-year, while earnings growth is N/A due to the absence of positive earnings, highlighting a divergence where top-line expansion is outpacing profitability improvements. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, indicating a strategy where earnings are entirely reinvested into research, development, and commercialization efforts rather than distributed to shareholders. This reinvestment approach is typical for biopharmaceutical companies in the specialty drug space, prioritizing the advancement of their dermatological product portfolio over immediate income generation for investors. The overall growth and income profile is defined by significant sales expansion coupled with financial losses, reflecting a high-risk, high-reward trajectory common in the Drug Manufacturers - Specialty & Generic industry where future cash flows depend on the successful commercialization of current and future pharmaceutical products.